Bone-breaking cancer treatment.
Roodman
G David
GD
D000818:Animals; D001859:Bone Neoplasms / Q000139:chemically induced* / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008954:Models, Biological; D016328:NF-kappa B / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
D016328:NF-kappa B; D016178:Granulocyte-Macrophage Colony-Stimulating Factor